Skip to main content
. Author manuscript; available in PMC: 2012 Sep 24.
Published in final edited form as: Eur Urol. 2010 Nov 24;59(5):747–754. doi: 10.1016/j.eururo.2010.11.024

Fig. 4.

Fig. 4

Effect of the volume of the PRX302 deposit. Combined average plus or minus standard error for (A) International Prostate Symptom Score (IPSS) and (B) quality of life score in men in the phase 1 and 2 studies receiving either <1 ml or ≥1 ml per deposit of PRX302 at a fixed concentration of 3 μg/ml (p < 0.01 for all data points). (C and D) Percent change in IPSS values at day 90 and day 360 compared to day 0 in men in the phase 1 (gray bars) and phase 2 (black bars) studies receiving <1 ml or ≥1 ml per deposit of PRX302.

IPSS = International Prostate Symptom Score; QoL = quality of life.